Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IIb multi-center, randomized, double-blind, placebo-controlled trial of PH10 in patients with major depressive disorder

Next Previous
Trial Profile

A phase IIb multi-center, randomized, double-blind, placebo-controlled trial of PH10 in patients with major depressive disorder

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Itruvone (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors VistaGen Therapeutics

Most Recent Events

  • 05 Nov 2024 According to a VistaGen media release, data from the study will be presented at the 2024 Neuroscience Education Institute (NEI) Congress in Colorado Springs, Colorado from November 7 to 10, 2024.
  • 09 Nov 2023 According to a VistaGen media release, the company will Initiate Phase 2B study in the second half of 2024.
  • 11 Aug 2022 According to a VistaGen Therapeutics media release, the company has planned initiation of a small U.S. Phase 1 study in 2022 to facilitate potential Phase 2B development of PH10 as a rapid-onset, stand-alone treatment of MDD in 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top